K-V Pharma (KV.A) Sues FDA, Says Unlawful Competition to Makena Could Lead to Bankruptcy; Shares Nosedive

Shares of the tiny but hotly-traded K-V Pharma (NYSE: KV-A) are getting smashed Friday as the company announced late Thursday it has sued the FDA, alleging the Administration needs to limit "unlawful competition" to K-V's Makena or it may go bankrupt. K-V said competing premature-birth products administered illegally could dwindle the company's capital for operations to nothing within three to six months.

The news follows a 15 percent surge in shares of K-V Pharma on Monday of this week after the FDA provided guidance on Makena.

K-V shares are down more than 21 percent to $0.51 at last check.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• HUB Cyber Security (HUBC) Strongly Responds To Dominion’s Misleading Lawsuit; Reaffirms Dedication To Expansion And Worldwide Customer Support
• Spirit Airlines (SAVE) Announces Resignation of Dawn M. Zier from Board
• Newmont (NEM) Appoints Francois Hardy as CTO